A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

PURPOSE: Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and combination use in a phase I study. PATIENTS AND METHODS: A phase I, multicenter, open-label dose-escalation study (NCT0273461...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhaveri, Komal, Juric, Dejan, Yap, Yoon-Sim, Cresta, Sara, Layman, Rachel M., Duhoux, Francois P., Terret, Catherine, Takahashi, Shunji, Huober, Jens, Kundamal, Nicole, Sheng, Qing, Balbin, Alejandro, Ji, Yan, He, Wei, Crystal, Adam, De Vita, Serena, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401512/
https://www.ncbi.nlm.nih.gov/pubmed/34433648
http://dx.doi.org/10.1158/1078-0432.CCR-21-1095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401512/
https://www.ncbi.nlm.nih.gov/pubmed/34433648
http://dx.doi.org/10.1158/1078-0432.CCR-21-1095

Ejemplares similares